India Mucormycosis Treatment (Black Fungus Drugs) Market
Overview
Mucormycosis (recently called zygomycosis) is a critical yet interesting parasitic disease brought about by a gathering of molds called mucormycetes. Additionally, breathing in contagious spores from the air can influence the lungs and sinuses. The parasite additionally attacks the skin through injuries like cuts, scratches, bruising, or other sorts of skin injuries. Contagious diseases might affect anybody, but they are most normal in individuals with debilitated resistant frameworks and can happen in almost any part of the body. Hazard factors for creating mucormycosis incorporate uncontrolled diabetes, malignant growth, organ relocation, neutropenia, and skin injury. Mucormycosis should be treated with an endorsed antifungal drug like amphotericin B, posaconazole, or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are meds given intravenously. Besides, posaconazole and isavuconazole can likewise be managed orally.
Effect of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic is expected to drive growth in the Indian Mucormycosis Treatment (Black Fungus Drugs) market over the forecast timeframe, owing to rising cases of mucormycosis contamination in COVID-19 positive patients or patients who have recovered from COVID-19 disease.COVID-19 disease has been linked to a wide range of bacterial and contagious contaminations, according to an article published in the Diabetes and Metabolic Syndrome Journal on May 21, 2021.Presently, mucormycosis contamination cases are ascending in the Indian populace due to the presence of ideal conditions in the COVID-19 patients: low oxygen, high glucose (in the event of diabetes or steroids induced hyperglycemia), acidic medium (diabetic ketoacidosis and others), high iron levels, and a smothered insusceptible framework alongside other comorbidities.
𝐓𝐨 𝐠𝐞𝐭 𝐌𝐨𝐫𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 @ https://www.coherentmarketinsights.com/insight/request-sample/4444
India Mucormycosis Treatment (Black Fungus Drugs) market had a valuation of US$ 9.1 million in 2021 and is anticipated to grow at a CAGR of 3.5% over the estimated timeframe (2021-2028).
Drivers
Market players are occupied with getting a permit from the Indian government to make Amphotericin-B, an enemy of parasitic medication, for the treatment of black fungus, or mucormycosis. This is anticipated to drive the development of the India Mucormycosis Treatment (Black Fungus Drugs) market over the conjectured timeframe.
The Indian government has given permission to a portion of the market players to make the anti-parasitic medication, Amphotericin-B, for the treatment of mucormycosis (Black Fungus Drugs). On May 22, 2021, the Indian government gave permits to five producers: Emcure Pharmaceuticals, Natco Pharmaceuticals, Gufic Biosciences, Alembic Pharmaceuticals, and Lyca Pharmaceuticals. These organizations will begin delivering 111,000 vials of Amphotericin-B every month from July 2021.
Vital participants are occupied with going into an arrangement to make a case against parasitic medications for dark growth. This is anticipated to drive the development of the India Mucormycosis Treatment (Black Fungus Drugs) market over the conjectured timeframe.
The expanding arrangements by the market players for the assembling of hostile to contagious medication in the treatment of mucormycosis is projected to drive the development of the India mucormycosis treatment (black fungus drugs) market over the estimated timeframe. On May 26, 2021, Cadila Healthcare Limited and TLC Pharma Labs entered into a consent to produce hostile to contagious medication “Liposomal Amphotericin B” for the treatment of mucormycosis, or dark parasite, in India.
The increasing pervasiveness of mucormycosis in the Indian populace with comorbidities is estimated to drive the development of the India Mucormycosis Treatment (Black Fungus Drugs) market.
𝐆𝐞𝐭 𝐅𝐮𝐥𝐥 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐩𝐨𝐫𝐭: (𝐈𝐧𝐜𝐥𝐮𝐝𝐢𝐧𝐠 𝐅𝐮𝐥𝐥 𝐓𝐎𝐂, 𝐋𝐢𝐬𝐭 𝐨𝐟 𝐓𝐚𝐛𝐥𝐞𝐬 & 𝐅𝐢𝐠𝐮𝐫𝐞𝐬, 𝐂𝐡𝐚𝐫𝐭) @ https://www.coherentmarketinsights.com/insight/request-pdf/4444
In India, diabetes mellitus is the most well-known fundamental illness. As per the article distributed in the Microorganism Journal, on March 4, 2021, the pie diagram shows the level of mucormycosis trouble in various in danger populations in India. As per a similar source, diabetes mellitus is a typical inclining factor for the rhino-orbital-cerebral mucormycosis (ROCM) kind of infection. A new report from India revealed that 77% of ROCM cases were in the diabetic populace.
Besides, as per the article distributed by the Indian Ministry of Chemicals and Fertilizers, around 8,848 instances of mucormycosis has been accounted for till May 25, 2021 in India. The accompanying diagram shows the quantity of instances of mucormycosis disease revealed in each state in India, till May 25, 2021.
Limitations
The high cost of medications used to treat mucormycosis is expected to limit the growth of the India Mucormycosis Treatment (Black Fungus Drugs) market over the forecasted timeframe. Main antifungal medication, amphotericin B, is costly, and it will be challenging for individuals to bear the expense. Presently, a single vial of the medication is accessible in the India mucormycosis treatment (black fungus drugs) market at a cost of US$ 68.6 to US$ 109.9 (5,000 to 8,000 Indian rupees). Additionally, the prescriptions must be taken for 4 to 12 weeks. Hence, numerous patients neglect to take the treatment due to significant expense. Government mediation might help in controlling the expense of the prescriptions.
Besides, drug deficiencies are another element that might hamper the development of the India mucormycosis treatment (black fungus drugs) market. Kerala, a state in South India, pronounced Amphotericin B lacking on the lookout. In addition, a normal mucormycosis patient requires 100 vials of Amphotericin B for their treatment. Subsequently, India will expect 9 to 10 lakh infusions of Amphotericin B for 9,000 mucormycosis patients. Consequently, the above factors are foreseen to control the development of the India Mucormycosis Treatment (Black Fungus Drugs) market over the estimated timeframe.
Competitive Landscape
Key companies contributing to the India mucormycosis treatment (black fungus drugs) market include Bharat Serums and Vaccines, Cipla Limited, Lyca Pharmaceuticals, Synbiotics Limited, Alembic Pharmaceuticals, Cadila Healthcare Limited, Natco Pharmaceuticals, TLC Pharma Labs, Gufic Biosciences, Kamla Lifesciences, Emcure Pharmaceuticals, Lifecare Innovations, and BDR Pharmaceuticals.
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐅𝐅 @ https://www.coherentmarketinsights.com/promo/buynow/4444
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drugs
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Regulatory Scenario
- PEST Analysis
- Recent Product Launch/Approval
- Epidemiology
- Diagnosis and Treatment Overview
- Competitive Intelligence
- Prescription Pattern
- Physicians Preferences and Views
- Market Dynamics
- India Mucormycosis Treatment (Black Fungus Drugs) Market – Impact of Coronavirus (Covid-19) Pandemic
- Impact on Supply Chain
- Impact on Diagnosis and Treatment
- Impact on Research and Development
- India Mucormycosis Treatment (Black Fungus Drugs) Market, By Drugs 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Amphotericin B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Isavuconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Posaconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Voriconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Flucytosine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Fluconazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- India Mucormycosis Treatment (Black Fungus Drugs) Market, By Distribution Channel, 2017 – 2028 (US$ Million)
- Introduction
- Market Share Analysis, 2021 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
- Introduction
- Competitive Landscape
- Company Profiles
- Natco Pharmaceuticals
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Alembic Pharmaceuticals
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Gufic Biosciences
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Lyca Pharmaceuticals
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Emcure Pharmaceuticals
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Bharat Serums and Vaccines
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- BDR Pharmaceuticals
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Cipla Limited
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Lifecare Innovations
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Synbiotics Limited
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Kamla Lifesciences
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Cadila Healthcare Limited
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- TLC Pharma Labs
- Company Overview
- Drug Type Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Natco Pharmaceuticals
- Company Profiles
- Section
- References
- Research Methodology
- About us and Sales Contact
View Press Release: https://www.coherentmarketinsights.com/press-release/india-mucormycosis-treatment-market-3709
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837